Listen Top Shows Blog

Patient-specific peptide vaccines

Patient-specific peptide vaccines

Update: 2017-07-28

Share

Description

Prof Rammensee speaks with ecancer at WIN 2017 about assessing the human leukocyte antigen (HLA) rearrangements of cancer patients to determine new targets for therapies.

He summarises the 'ligandome' and its role in directing T cell response, noting mutation-high tumours responding more to checkpoint immunotherapy, and describes how peptides derived from ligand assays could help design cancer vaccines.

Comments

In Channel

Molecular medicine in lung cancer

Molecular medicine in lung cancer

2017-07-3106:34

Precision medicine enabled histology agnostic development of immunotherapeutics

Precision medicine enabled histology agnostic development of immunotherapeutics

2017-07-3108:22

Synthetic lethality as a basis to select drug combinations

Synthetic lethality as a basis to select drug combinations

2017-07-3108:32

Genomic predictors of treatment response in prostate cancer

Genomic predictors of treatment response in prostate cancer

2017-07-3104:59

Redesigning clinical trials in the era of precision medicine

Redesigning clinical trials in the era of precision medicine

2017-07-3105:42

Novel models to personalise cancer therapeutics

Novel models to personalise cancer therapeutics

2017-07-3107:35

Genomic analysis of childhood tumours; biological and therapeutic implications

Genomic analysis of childhood tumours; biological and therapeutic implications

2017-07-3104:56

Biomarker research in breast cancer

Biomarker research in breast cancer

2017-07-3105:39

Big data, scientific wellness and transforming healthcare

Big data, scientific wellness and transforming healthcare

2017-07-3107:36

Genomic-driven clinical studies in breast cancer

Genomic-driven clinical studies in breast cancer

2017-07-3105:49

Current and future immune approaches in precision medicine

Current and future immune approaches in precision medicine

2017-07-3109:50

Bayesian adaptive trial designs for precision medicine

Bayesian adaptive trial designs for precision medicine

2017-07-3106:23

Proteogenomics in cancer research

Proteogenomics in cancer research

2017-07-2805:27

Patient-specific peptide vaccines

Patient-specific peptide vaccines

2017-07-2806:31

DNA damage response inhibition

DNA damage response inhibition

2017-07-2804:04

New biomarkers for response to immunotherapy

New biomarkers for response to immunotherapy

2017-07-2806:47

Incorporating liquid biopsies into clinical trials

Incorporating liquid biopsies into clinical trials

2017-07-2810:09

Combining immune-based therapies with TKIs in melanomas

Combining immune-based therapies with TKIs in melanomas

2017-07-2802:51

00:00

00:00

x

Patient-specific peptide vaccines

Patient-specific peptide vaccines

Prof Hans-Georg Rammensee - University of Tübingen, Tübingen, Germany